Cargando…

Vedolizumab Attenuates Immune-Checkpoint-Therapy-Induced Infliximab-Refractory Colitis

Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab, have drastically changed treatments of advanced melanoma. However, ICI-related enterocolitis is often the most common adverse event, and represents the main reason for ICI discontinuation and mortalities. Here, we report the case...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaneoka, Ayaka, Okada, Etsuko, Sugino, Hitomi, Saito-Sasaki, Natsuko, Omoto, Daisuke, Nakamura, Motonobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870896/ https://www.ncbi.nlm.nih.gov/pubmed/35204571 http://dx.doi.org/10.3390/diagnostics12020480

Ejemplares similares

Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report
por: Randhawa, Manreet, et al.
Publicado: (2019)

Ixekizumab‐induced urticarial drug eruption
por: Kaneoka, Ayaka, et al.
Publicado: (2023)

Vedolizumab is superior to infliximab in biologic naïve patients with ulcerative colitis
por: Sablich, Renato, et al.
Publicado: (2023)

Cardiac Arrest Due to Kounis Syndrome Following Cephazolin Administration During Surgery Under Local Anesthesia
por: Obata, Ayaka, et al.
Publicado: (2023)

STING expression is an independent prognostic factor in patients with mycosis fungoides
por: Takayanagi-Hara, Reiko, et al.
Publicado: (2022)

High S100A2 expression in keratinocytes in patients with drug eruption
por: Yoshioka, Manabu, et al.
Publicado: (2021)

Psoriasis epidemiology screening tool (PEST) is useful for the detection of psoriatic arthritis in the Japanese population
por: Setoyama, Ayako, et al.
Publicado: (2021)

A Positive Dermcidin Expression Is an Unfavorable Prognostic Marker for Extramammary Paget’s Disease
por: Ohmori, Shun, et al.
Publicado: (2021)

Prior antihistamine agent successfully impaired cutaneous adverse reactions to COVID‐19 vaccine
por: Nanamori, Hikaru, et al.
Publicado: (2022)

Cell Adhesion Molecule 1 (CADM1) Is an Independent Prognostic Factor in Patients with Cutaneous Squamous Cell Carcinoma
por: Saito-Sasaki, Natsuko, et al.
Publicado: (2021)

Successful Treatment of Ulcerative Colitis With Vedolizumab in a Patient With an Infliximab-Associated Psoriasiform Rash
por: Hirsch, Ayal, et al.
Publicado: (2015)

Cost-effectiveness of adalimumab, infliximab or vedolizumab as first-line biological therapy in moderate-to-severe ulcerative colitis
por: Yokomizo, Lauren, et al.
Publicado: (2016)

A Retrospective Study of Superficial Type Atypical Lipomatous Tumor
por: Mashima, Emi, et al.
Publicado: (2020)

Vedolizumab in the treatment of immune checkpoint inhibitor-induced colitis: Two case reports
por: Zhang, Zhe, et al.
Publicado: (2022)

Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
por: Petryszyn, Pawel, et al.
Publicado: (2020)

Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor–Induced Enteritis
por: Diana, Pietro, et al.
Publicado: (2018)

Refractory Ulcerative Colitis Improved by Scheduled Combination Therapy of Vedolizumab and Granulocyte and Monocyte Adsorptive Apheresis
por: Nakamura, Masanao, et al.
Publicado: (2020)

Anaphylactoid purpura triggered by cellulitis as a favorable prognosis: case report and literature review
por: Saito-Sasaki, Natsuko, et al.
Publicado: (2016)

Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center
por: Gagnon, Ann-Lorie, et al.
Publicado: (2021)

Neutrophil-to-Platelet Ratio in Patients with Ulcerative Colitis Treated with Infliximab or Vedolizumab: A Retrospective, Single-Center Study in Poland
por: Warpechowski, Marcin, et al.
Publicado: (2023)

Combination of vedolizumab and immunomodulators in ulcerative colitis
por: Pinton, P
Publicado: (2021)

Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China
por: Zhou, Ting, et al.
Publicado: (2021)

Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study
por: Zou, Fangwen, et al.
Publicado: (2021)

Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
por: Xie, Feng, et al.
Publicado: (2009)

Mild hypertrichosis in both upper arms around dupilumab injection sites
por: Sugino, Hitomi, et al.
Publicado: (2021)

Vedolizumab for chronic antibiotic-refractory pouchitis
por: Singh, Amandeep, et al.
Publicado: (2019)

Vedolizumab Is Associated with Longer Drug Sustainability Compared to Infliximab in Moderate-to-Severe Ulcerative Colitis: Long-Term Real-World Cohort Data
por: Konikoff, Tom, et al.
Publicado: (2023)

Cytomegalovirus Colitis in a Patient With Ulcerative Colitis on Vedolizumab Monotherapy
por: Meeralam, Yaser, et al.
Publicado: (2023)

Infliximab/vedolizumab: Drug-induced lupus, pneumonitis and lack of efficacy: case report
Publicado: (2021)

Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2018)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Infliximab for Steroid-Refractory Immune Checkpoint Inhibitor-Induced Acute Pancreatitis
por: Townsend, Matthew J., et al.
Publicado: (2023)

Vedolizumab Therapy in Refractory Enteropathy Associated With CVID
por: Johnson, Dane, et al.
Publicado: (2021)

Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations
por: Burdge, Gemma, et al.
Publicado: (2022)

Maresin-1 suppresses imiquimod-induced skin inflammation by regulating IL-23 receptor expression
por: Saito-Sasaki, Natsuko, et al.
Publicado: (2018)

Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis
por: Saito, Daisuke, et al.
Publicado: (2021)

IgA Vasculitis: Etiology, Treatment, Biomarkers and Epigenetic Changes
por: Sugino, Hitomi, et al.
Publicado: (2021)

Infliximab in ulcerative colitis
por: Levin, Avi, et al.
Publicado: (2008)

Patient considerations in the management of ulcerative colitis – role of vedolizumab
por: Kothari, Megha, et al.
Publicado: (2015)

Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis
por: Subhaharan, Deloshaan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_70cvbnpoq1iph97mr8jqr037np